This study focuses on individuals with Pancreatic Ductal Adenocarcinoma, which is a type of cancer that begins in the ducts of the pancreas. The research specifically involves patients who have undergone surgical removal of the tumor, known as resected cancer, and have already finished neoadjuvant or adjuvant chemotherapy. Neoadjuvant refers to treatment given before surgery to shrink a tumor, while adjuvant refers to treatment given after surgery to help remove any remaining cancer cells.

The purpose of this study is to compare the effectiveness of a new drug called daraxonrasib, also known by its code name RMC-6236, against the current standard of care, which involves close observation by medical professionals. Daraxonrasib is an oral medication taken in the form of a tablet.

During the study, participants are assigned to one of two groups through a process called randomization. One group will receive the experimental drug, while the other group will receive the standard observation. The course of the study involves monitoring patients over time to see how long they remain free from the disease and to track overall survival.